Enarodustat to treat anemia in chronic kidney disease

被引:1
作者
Fukui, K. [1 ,2 ]
Tanaka, T. [1 ]
Nangaku, M. [1 ]
机构
[1] Univ Tokyo Hosp, Div Nephrol & Endocrinol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[2] Japan Tobacco Inc, Cent Pharmaceut Res Inst, Takatsuki, Osaka, Japan
关键词
Enarodustat; Anemia; Chronic kidney disease; Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors; Antianemics; Renal disorders; PROLYL HYDROXYLASE INHIBITOR; ERYTHROPOIESIS; HEMODIALYSIS; OUTCOMES; RESPONSES; JTZ-951;
D O I
10.1358/dot.2021.57.8.3304877
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Anemia is a common complication in patients with chronic kidney disease (CKD). Erythropoiesis-stimulating agents (ESAs) are the standard therapy for anemia in CKD. It has been expected that hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibition may have the potential to provide therapeutic benefits over pre-existing ESAs for anemia in CKD. Enarodustat (JTZ-951) is an oral HIF-PH inhibitor. In preclinical studies, enarodustat has been found to increase HIF-alpha proteins, erythropoietin production and erythropoiesis. Enarodustat also shows efficient iron utilization in iron-related parameters during erythropoiesis. Clinical trials have shown that enarodustat improved anemia both in non-dialysis-dependent CKD patients and dialysis patients. The safety results in clinical trials demonstrate that enarodustat is generally well tolerated. On the basis of these results, enarodustat was approved in September 2020 in Japan for the treatment of anemia associated with CKD. This manuscript will review enarodustat, its pharmacological characteristics in preclinical studies, and its efficacy and safety in clinical trials with anemic patients in CKD.
引用
收藏
页码:491 / 497
页数:7
相关论文
共 33 条
  • [1] Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS
    Akizawa, Tadao
    Pisoni, Ronald L.
    Akiba, Takashi
    Saito, Akira
    Fukuhara, Shunichi
    Asano, Yasushi
    Hasegawa, Takeshi
    Port, Friedrich K.
    Kurokawa, Kiyoshi
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (11) : 3643 - 3653
  • [2] A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study
    Akizawa, Tadao
    Nangaku, Masaomi
    Yamaguchi, Takuhiro
    Koretomo, Ryosuke
    Maeda, Kazuo
    Miyazawa, Yuya
    Hirakata, Hideki
    [J]. KIDNEY INTERNATIONAL REPORTS, 2021, 6 (07): : 1840 - 1849
  • [3] A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study
    Akizawa, Tadao
    Nangaku, Masaomi
    Yamaguchi, Takuhiro
    Koretomo, Ryosuke
    Maeda, Kazuo
    Miyazawa, Yuya
    Hirakata, Hideki
    [J]. KIDNEY DISEASES, 2021, 7 (06) : 494 - 502
  • [4] Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial
    Akizawa, Tadao
    Nangaku, Masaomi
    Yamaguchi, Takuhiro
    Arai, Masanobu
    Koretomo, Ryosuke
    Maeda, Kazuo
    Miyazawa, Yuya
    Hirakata, Hideki
    [J]. NEPHRON, 2019, 143 (02) : 77 - 85
  • [5] A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial
    Akizawa, Tadao
    Nangaku, Masaomi
    Yamaguchi, Takuhiro
    Arai, Masanobu
    Koretomo, Ryosuke
    Matsui, Atsushi
    Hirakata, Hideki
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2019, 49 (02) : 165 - 174
  • [6] Arai M., 2015, NEPHROL DIAL TRANSPL, V30, P196
  • [7] Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease
    Artunc, Ferruh
    Risler, Teut
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (10) : 2900 - 2908
  • [8] Enaroy (Enarodustat), EN EN JAP PRESCR INF
  • [9] JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor
    Fukui, Kenji
    Shinozaki, Yuichi
    Kobayashi, Hatsue
    Deai, Katsuya
    Yoshiuchi, Hiromi
    Matsui, Takuya
    Matsuo, Akira
    Matsushita, Mutsuyoshi
    Tanaka, Tetsuhiro
    Nangaku, Masaomi
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 859
  • [10] Impact of Erythropoiesis-Stimulating Agents on Energy and Physical Function in Nondialysis CKD Patients With Anemia: A Systematic Review
    Gandra, Shravanthi R.
    Finkelstein, Fredric O.
    Bennett, Antonia V.
    Lewis, Eldrin F.
    Brazg, Tracy
    Martin, Mona L.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (03) : 519 - 534